Clinical-stage oncology company developing tumor-activated drug conjugates that combine established and emerging cancer medicines into simpler, potentially safer combination therapies
Clinical-stage oncology company developing tumor-activated drug conjugates that combine established and emerging cancer medicines into simpler, potentially safer combination therapies. Its lead candidate, DUO-207, is designed to combine gemcitabine and paclitaxel in a single infusion for pancreatic, lung, and breast cancers, with additional preclinical programs in other cancers.